AstraZeneca Pharmaceuticals, (AZN) is one of the world's leading pharmaceutical companies with 57,000 employees worldwide in over 100 countries. Its corporate headquarters are in London, research and development headquarters are in Södertälje, Sweden, and its manufacturing facilities employ 9,600 people in 16 different countries. The company operates fourteen research and development sites in eight countries and has sales in over 100 countries around the world. AstraZeneca focuses its pharmaceutical business on seven key therapeutic areas: anesthesia and pain control, cardiovascular, central nervous system, gastrointestinal (it is a world leader in this therapeutic area), infection, oncology, and respiratory. Its product range includes such blockbusters as Nexium, Crestor, Seroquel, and Symbicort.
AstraZeneca was formed as the result of the 1999 merger of two European pharmaceuticals companies: Astra AB of Sweden, a maker of pharmaceutical products and medical devices, and Zeneca PLC of the United Kingdom, a bioscience company focusing on pharmaceuticals, agricultural and specialty chemicals, and disease-specific healthcare services. One year after its merger, the company achieved sales of US$15.8 billion, with an operating profit of US$4 billion. In 2011, company sales and operating profit were $33.6 billion and $13.2 billion respectively.
AstraZeneca is one of the world's largest pharmaceutical companies, with FY2011 sales of $33.27 billion and $10.98 billion in profits before taxes. AstraZeneca's wide-ranging portfolio of products includes some of the world's most successful drugs. Analysts credit AstraZeneca with having one of the most diversified drug portfolios in the pharmaceutical industry. In all, AstraZeneca has 9 blockbuster drugs (with $1 billion or more in annual sales) in five different therapeutic categories. All in all, these products generated 75% of the company's revenue in 2011.
Despite sunny short term prospects,...